NeuroSense Therapeutics’ (NRSN) Sell (D-) Rating Reaffirmed at Weiss Ratings

NeuroSense Therapeutics (NASDAQ:NRSN)‘s stock had its “sell (d-)” rating reiterated by equities research analysts at Weiss Ratings in a research report issued on Saturday,Weiss Ratings reports.

Other analysts have also issued reports about the stock. Zacks Research upgraded shares of NeuroSense Therapeutics to a “hold” rating in a research note on Wednesday, October 15th. D. Boral Capital restated a “buy” rating and set a $14.00 target price on shares of NeuroSense Therapeutics in a research report on Friday, August 15th. Finally, Noble Financial upgraded shares of NeuroSense Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 14th. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $14.00.

NeuroSense Therapeutics Trading Up 1.7%

Shares of NRSN stock opened at $1.18 on Friday. The company has a 50 day moving average price of $1.19 and a 200-day moving average price of $1.45. NeuroSense Therapeutics has a 52 week low of $0.80 and a 52 week high of $2.60.

Hedge Funds Weigh In On NeuroSense Therapeutics

A hedge fund recently bought a new stake in NeuroSense Therapeutics stock. Jane Street Group LLC purchased a new stake in shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 28,689 shares of the company’s stock, valued at approximately $54,000. Jane Street Group LLC owned approximately 0.21% of NeuroSense Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 1.04% of the company’s stock.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.